Showing 1 - 16 of 16 Items
Showing 1 - 16 of 16 Items
Sort By: Relevance
Journal Article
|Research
2025-02-18 • Clinical Infectious Diseases
2025-02-18 • Clinical Infectious Diseases
BACKGROUND
Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...
Journal Article
|Research
2025-02-01 • Lancet Global Health
2025-02-01 • Lancet Global Health
BACKGROUND
New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...
Journal Article
|Research
2024-09-01 • IJTLD OPEN
2024-09-01 • IJTLD OPEN
BACKGROUND
Dru...
Journal Article
|Letter
2024-08-15 • Clinical Infectious Diseases
2024-08-15 • Clinical Infectious Diseases
Journal Article
|Research
2024-02-01 • Lancet Respiratory Medicine
2024-02-01 • Lancet Respiratory Medicine
BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
Conference Material
|Poster
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Journal Article
|Research
2022-12-22 • New England Journal of Medicine
2022-12-22 • New England Journal of Medicine
BACKGROUND
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...
Journal Article
|Research
2021-12-04 • Trials
2021-12-04 • Trials
BACKGROUND
Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF)...
Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF)...
Journal Article
|Research
2020-09-16 • BMC Infectious Diseases
2020-09-16 • BMC Infectious Diseases
Introduction: Person-centred care, an internationally recognised priority, describes the involvement of people in their care and treatment decisions, and the consideration of their needs...
Conference Material
|Abstract
2020-05-20 • MSF Scientific Days International 2020: Research
2020-05-20 • MSF Scientific Days International 2020: Research
INTRODUCTION
Person-centred care (PCC) is an internationally recognised priority, and a key underlying principle within MSF projects. PCC ensures that people are involved in their ca...
Person-centred care (PCC) is an internationally recognised priority, and a key underlying principle within MSF projects. PCC ensures that people are involved in their ca...
Journal Article
|Letter
2015-09-09 • Emerging Infectious Diseases
2015-09-09 • Emerging Infectious Diseases
Journal Article
|Research
2013-11-06 • PLOS One
2013-11-06 • PLOS One
BACKGROUND
The Médecins Sans Frontières project of Uzbekistan has provided multidrug-resistant tuberculosis treatment in the Karakalpakstan region since 2003. Rates of default from t...
The Médecins Sans Frontières project of Uzbekistan has provided multidrug-resistant tuberculosis treatment in the Karakalpakstan region since 2003. Rates of default from t...
Journal Article
|Research
2020-11-25 • PLOS One
2020-11-25 • PLOS One
Introduction
Standard multidrug-resistant tuberculosis (MDR-TB) treatment is lengthy, toxic, and insufficiently effective. New drugs and a shorter treatment regimen (SCR) are now re...
Standard multidrug-resistant tuberculosis (MDR-TB) treatment is lengthy, toxic, and insufficiently effective. New drugs and a shorter treatment regimen (SCR) are now re...
Journal Article
|Research
2016-07-28 • BMC Infectious Diseases
2016-07-28 • BMC Infectious Diseases
BACKGROUND
Treatment for multi-drug resistant tuberculosis (MDR-TB) is lengthy, has severe side effects, and raises adherence challenges. In the Médecins Sans Frontières (MSF) and Mi...
Treatment for multi-drug resistant tuberculosis (MDR-TB) is lengthy, has severe side effects, and raises adherence challenges. In the Médecins Sans Frontières (MSF) and Mi...
Journal Article
|Research
2021-02-08 • ERJ open research
2021-02-08 • ERJ open research
BACKGROUND
In 2016, World Health Organization guidelines conditionally recommended standardised shorter 9–12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment....
In 2016, World Health Organization guidelines conditionally recommended standardised shorter 9–12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment....
Journal Article
|Research
2018-05-01 • International Journal of Tuberculosis and Lung Disease
2018-05-01 • International Journal of Tuberculosis and Lung Disease
SETTING
The World Health Organization (WHO) recommends the inclusion of pyrazinamide (PZA) in treatment regimens for multidrug-resistant tuberculosis (MDR-TB) unless resistance has b...
The World Health Organization (WHO) recommends the inclusion of pyrazinamide (PZA) in treatment regimens for multidrug-resistant tuberculosis (MDR-TB) unless resistance has b...